Antoinette R. Tan

home / authors / antoinette-r-tan

Articles

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath M. Jeselsohn;Pamela N. Munster, MD;Eric Zhi;Elizabeth Duperret;Cecile Mather;Erika P. Hamilton, MD;Hyo S Han
August 4th 2024
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Erika P. Hamilton, MD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath Jeselsohn;Pamela N. Munster, MD;Haolan Lu;Richard Gedrich;Cecile Mather;Janaki Parameswaran;Hyo S Han
April 27th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship
Published: November 7th 2024 | Updated: November 21st 2024
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Published: November 7th 2024 | Updated: November 21st 2024
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Treatment Considerations for Disease Progression
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Considerations for Disease Progression